<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Stroke</journal-id><journal-id journal-id-type="iso-abbrev">J Stroke</journal-id><journal-id journal-id-type="publisher-id">JOS</journal-id><journal-title-group><journal-title>Journal of Stroke</journal-title></journal-title-group><issn pub-type="ppub">2287-6391</issn><issn pub-type="epub">2287-6405</issn><publisher><publisher-name>Korean Stroke Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4325636</article-id><article-id pub-id-type="doi">10.5853/jos.2015.17.1.17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Special Review</subject><subj-group subj-group-type="heading"><subject>Small Vessel Disease I</subject></subj-group></subj-group></article-categories><title-group><article-title>Cerebral Amyloid Angiopathy: Emerging Concepts</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Yamada</surname><given-names>Masahito</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1">Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.</aff><author-notes><corresp>Correspondence: Masahito Yamada. Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa 920-8640, Japan. Tel: +81-76-265-2290, Fax: +81-76-234-4253, <email>m-yamada@med.kanazawa-u.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>30</day><month>1</month><year>2015</year></pub-date><volume>17</volume><issue>1</issue><fpage>17</fpage><lpage>30</lpage><history><date date-type="received"><day>13</day><month>11</month><year>2014</year></date><date date-type="rev-recd"><day>15</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>24</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Korean Stroke Society</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Cerebral amyloid angiopathy (CAA) involves cerebrovascular amyloid deposition and is classified into several types according to the amyloid protein involved. Of these, sporadic amyloid &#x003b2;-protein (A&#x003b2;)-type CAA is most commonly found in older individuals and in patients with Alzheimer's disease (AD). Cerebrovascular A&#x003b2; deposits accompany functional and pathological changes in cerebral blood vessels (CAA-associated vasculopathies). CAA-associated vasculopathies lead to development of hemorrhagic lesions [lobar intracerebral macrohemorrhage, cortical microhemorrhage, and cortical superficial siderosis (cSS)/focal convexity subarachnoid hemorrhage (SAH)], ischemic lesions (cortical infarction and ischemic changes of the white matter), and encephalopathies that include subacute leukoencephalopathy caused by CAA-associated inflammation/angiitis. Thus, CAA is related to dementia, stroke, and encephalopathies. Recent advances in diagnostic procedures, particularly neuroimaging, have enabled us to establish a clinical diagnosis of CAA without brain biopsies. Sensitive magnetic resonance imaging (MRI) methods, such as gradient-echo T2<sup>*</sup> imaging and susceptibility-weighted imaging, are useful for detecting cortical microhemorrhages and cSS. Amyloid imaging with amyloid-binding positron emission tomography (PET) ligands, such as Pittsburgh Compound B, can detect CAA, although they cannot discriminate vascular from parenchymal amyloid deposits. In addition, cerebrospinal fluid markers may be useful, including levels of A&#x003b2;40 for CAA and anti-A&#x003b2; antibody for CAA-related inflammation. Moreover, cSS is closely associated with transient focal neurological episodes (TFNE). CAA-related inflammation/angiitis shares pathophysiology with amyloid-related imaging abnormalities (ARIA) induced by A&#x003b2; immunotherapies in AD patients. This article reviews CAA and CAA-related disorders with respect to their epidemiology, pathology, pathophysiology, clinical features, biomarkers, diagnosis, treatment, risk factors, and future perspectives.</p></abstract><kwd-group><kwd>Cerebral amyloid angiopathy</kwd><kwd>Amyloid &#x003b2;-protein</kwd><kwd>Cerebrovascular disorders</kwd><kwd>MRI</kwd><kwd>PET</kwd><kwd>Cerebrospinal fluid</kwd></kwd-group><funding-group><award-group><funding-source country="JP">Ministry of Health, Labor and Welfare</funding-source></award-group><award-group><funding-source country="JP">SENSHIN Medical Research Foundation</funding-source></award-group></funding-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Cerebral amyloid angiopathy (CAA) involves cerebrovascular amyloid deposition. CAA was described as a cause of normotensive cerebral hemorrhage in older individuals or also described in studies focusing on its close association with Alzheimer's disease (AD). The earlier terms to describe CAA include "dr&#x000fc;sige Entartung der Arterien und Kapillaren,"<xref rid="B1" ref-type="bibr">1</xref> "aniopathie dyshorique,"<xref rid="B2" ref-type="bibr">2</xref> and "angiopathie congophile."<xref rid="B3" ref-type="bibr">3</xref> The terms "dr&#x000fc;sige Entartung" and "angiopathie dyshorique" represent a peculiar form of CAA showing perivascular plaque-like structures. Currently, CAA has been used as a general term to describe cerebrovascular amyloid deposition or cerebrovascular amyloidosis.<xref rid="B4" ref-type="bibr">4</xref></p><p>CAA is classified into several types according to the amyloid protein involved (<xref ref-type="table" rid="T1">Table 1</xref>). So far, seven amyloid proteins have been reported in CAA including amyloid &#x003b2;-protein (A&#x003b2;), cystatin C (ACys), prion protein (APrP), ABri/ADan, transthyretin (ATTR), gelsolin (AGel), and immunoglobulin light chain amyloid (AL); among these, sporadic CAA of the A&#x003b2; type is most commonly found in older individuals as well as in patients with AD [see review<xref rid="B5" ref-type="bibr">5</xref>].</p><p>This article reviews sporadic A&#x003b2;-type CAA and CAA-related disorders with respect to their epidemiology, pathology, pathophysiology, clinical features, biomarkers, diagnosis, treatment, risk factors, and future perspectives.</p></sec><sec><title>Epidemiology, pathology, and pathophysiology of CAA</title><p>The prevalence of CAA increases with age,<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref> and CAA occurs in approximately half of elderly individuals.<xref rid="B6" ref-type="bibr">6</xref> CAA is commonly observed in AD with a prevalence of about 80%-90%.<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B8" ref-type="bibr">8</xref> CAA-related lobar intracerebral hemorrhage (ICH), identified via a nationwide survey in Japan, increases with age and presents with female predominance.<xref rid="B9" ref-type="bibr">9</xref></p><p>Pathologically, CAA is observed mainly in the leptomeningeal and cortical vessels of the cerebral lobes and cerebellum. For the distribution of CAA, the occipital lobe is preferentially affected,<xref rid="B6" ref-type="bibr">6</xref> whereas CAA is uncommon in the basal ganglia, thalamus, brainstem, and white matter. In mild CAA, a small proportion of the leptomeningeal and superficial cortical vessels are affected with amyloid deposition. In severe CAA, most small arteries and arterioles are affected with marked amyloid deposition. Medium-sized leptomeningeal arteries show amyloid deposition in the outer regions of the media to the adventitia. Vessel walls of the small arteries and arterioles are often totally replaced by amyloid deposits, except for the endothelial cells. Electron microscopically, amyloid fibrils are focally deposited within the outer basement membrane of the vessels during the initial stage of CAA.<xref rid="B10" ref-type="bibr">10</xref> Later, a large amount of amyloid fibrils accumulate with degeneration of smooth muscle cells of the media (<xref ref-type="fig" rid="F1">Figure 1A</xref>). Amyloid deposits in capillaries and, occasionally, in arterioles or small arteries appear to infiltrate the surrounding parenchymal tissue, and accompany dystrophic neurites forming plaque-like structures (dr&#x000fc;sige Entartung<xref rid="B1" ref-type="bibr">1</xref>/angiopathie dyshorique<xref rid="B2" ref-type="bibr">2</xref>). Recently, CAA in capillaries has been referred to as "capillary CAA (CAA-Type 1)," to distinguish it from non-capillary CAA (CAA-Type 2).<xref rid="B11" ref-type="bibr">11</xref> Severe CAA is associated with vasculopathies including duplication ("double-barrel" lumen), obliterative intimal changes, hyaline degeneration, microaneurysmal dilatation, and fibrinoid necrosis (<xref ref-type="fig" rid="F1">Figure 1B, C</xref>).<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref> These CAA-associated vasculopathies are the pathological basis of CAA-related cerebrovascular disorders. In particular, fibrinoid necrosis is closely associated with CAA-related hemorrhage.<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref></p><p>A&#x003b2; is cleaved from the &#x003b2;-amyloid precursor protein (A&#x003b2;PP) by &#x003b2;-secretase and &#x003b3;-secretase. Heterogeneity of the C-terminal is present, and the length of A&#x003b2; in senile plaques is mainly 42-43 residues (A&#x003b2;42), while that of cerebrovascular A&#x003b2; (CAA) is mainly 39-40 residues (A&#x003b2;40) (<xref ref-type="fig" rid="F2">Figure 2</xref>).<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref> Recent studies suggest that A&#x003b2; in CAA is derived from the brain [see review<xref rid="B5" ref-type="bibr">5</xref>]; after release from neurons, A&#x003b2;42 easily aggregates and deposits in the brain parenchyma as senile plaques; whereas, A&#x003b2;40 does not aggregate as easily as A&#x003b2;42, and is transported, through periarterial interstitial fluid drainage pathways, to blood vessels for clearance. In this process, A&#x003b2;40 aggregates on vascular basement membranes, as first proposed by Weller.<xref rid="B17" ref-type="bibr">17</xref></p><p>The pathophysiology of A&#x003b2;-type CAA is shown in <xref ref-type="fig" rid="F3">Figure 3</xref>.<xref rid="B18" ref-type="bibr">18</xref> CAA-associated vasculopathies lead to development of hemorrhagic lesions [lobar intracerebral macrohemorrhage, cortical microhemorrhage, and cortical superficial siderosis (cSS)/focal convexity subarachnoid hemorrhage (SAH)], ischemic lesions (cortical infarction and ischemic changes of the white matter), and encephalopathies that include subacute leukoencephalopathy caused by CAA-related inflammation/angiitis (<xref ref-type="fig" rid="F1">Figure 1</xref>). In addition, CAA is related to dementia through AD pathology and CAA-related vascular lesions (<xref ref-type="fig" rid="F1">Figure 1</xref>). Thus, CAA is related to dementia, stroke, and encephalopathies.</p></sec><sec><title>Clinical aspects of CAA-related disorders</title><sec><title>Clinical features</title><sec><title>Intracerebral hemorrhages</title><sec><title>Symptomatic lobar intracerebral hemorrhages (ICH)</title><p>CAA is significantly associated with lobar intracerebral hemorrhage (ICH) (<xref ref-type="fig" rid="F4">Figure 4A</xref>), but not with deep ICH,<xref rid="B19" ref-type="bibr">19</xref> because sporadic A&#x003b2;-type CAA is commonly found in the meningeal and cortical vessels of cerebral and cerebellar cortices, and rarely in those of the deep gray matter including basal ganglia, thalamus, and brainstem.<xref rid="B6" ref-type="bibr">6</xref> Using the SMASH-U system (structural lesion, medication, amyloid angiopathy, systemic/other disease, hypertension, undetermined) as a pathogenetic classification system for ICH, CAA-related ICH was noted in 20% of ICH cases in the Helsinki ICH study,<xref rid="B20" ref-type="bibr">20</xref> and 12% of ICH cases in the National Taiwan University Hospital Stroke Registry.<xref rid="B21" ref-type="bibr">21</xref> CAA-related ICH was the second most common cause of ICH following hypertensive angiopathy in these studies.<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref> The incidence of lobar ICH in the elderly has been increasing recently, in which CAA is strongly implicated.<xref rid="B22" ref-type="bibr">22</xref> CAA-related lobar ICH is often multiple and recurrent, and clinical manifestations include motor paresis, disturbance of consciousness, abnormalities in higher brain functions, such as aphasia, visual loss, with headache at the acute stage, and dementia and seizures during chronic stages.<xref rid="B9" ref-type="bibr">9</xref> Headache with meningeal signs is likely caused by subarachnoid hemorrhage (SAH) accompanying lobar ICH.<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref></p></sec><sec><title>Cortical microhemorrhages</title><p>Cerebral microhemorrhages (microbleeds) were noted in 16.7%-32% of AD patients, which is higher than in the general population (5%-6%), when examined by gradient-echo T2<sup>*</sup> MRI,<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref> and in 78% of patients with AD or mild cognitive impairment (MCI) on ultra-high field strength 7T MRI.<xref rid="B31" ref-type="bibr">31</xref> Microhemorrhages were found in 47.4% of patients with pathologically confirmed CAA cases.<xref rid="B32" ref-type="bibr">32</xref> CAA-related microhemorrhages are frequently lobar in distribution (<xref ref-type="fig" rid="F4">Figure 4B</xref>). Studies with amyloid positron emission tomography (PET) using 11C-Pittsburgh Compound B (PiB) reported that lobar microhemorrhages are frequently found in PiB-positive healthy subjects as well as patients with AD or mild cognitive impairment (MCI),<xref rid="B33" ref-type="bibr">33</xref> and that microhemorrhages preferentially occur in local regions of concentrated amyloid deposits.<xref rid="B34" ref-type="bibr">34</xref> New hemorrhages occur preferentially at the sites of increased amyloid deposits, suggesting that amyloid imaging may be useful to predict future CAA-related hemorrhages.<xref rid="B35" ref-type="bibr">35</xref> Patients with lobar microhemorrhages are at considerable risk of future symptomatic lobar ICH.<xref rid="B36" ref-type="bibr">36</xref></p></sec></sec><sec><title>Cortical superficial siderosis/focal convexity subarachnoid hemorrhages</title><p>CAA is a frequent cause of cSS/focal convexity SAH (<xref ref-type="fig" rid="F4">Figure 4C</xref>), a subtype of nonaneurysmal SAH, in patients over the age of 60 and in those with AD.<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref> Notably, cSS is closely associated with microhemorrhages in lobar locations in the general population.<xref rid="B39" ref-type="bibr">39</xref> Moreover, cSS occurs with high prevalence in CAA and is found in 60.5% of pathologically confirmed cases.<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B40" ref-type="bibr">40</xref> Interestingly, cSS tends to occur in individuals with relatively fewer cortical microhemorrhages, suggesting differences in vasculopathic changes between CAA-related microhemorrhages and cSS.<xref rid="B41" ref-type="bibr">41</xref> Furthermore, cSS is associated with an increased future risk of symptomatic lobar ICH.<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B42" ref-type="bibr">42</xref> The prevalence of cSS is higher in patients with AD or cognitive impairment than in the general population.<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B44" ref-type="bibr">44</xref> Interestingly, cSS has been reported to present with transient focal neurological episodes (TFNEs); TFNEs are a clinical marker of cSS and may be caused by cSS through cortical spreading depression or focal seizure activity.<xref rid="B45" ref-type="bibr">45</xref>,<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>,<xref rid="B48" ref-type="bibr">48</xref>,<xref rid="B49" ref-type="bibr">49</xref> Anti-platelet or anticoagulant therapies based on the misdiagnosis of CAA-related TFNE as a transient ischemic attack may induce CAA-related ICH.</p></sec><sec><title>White matter disease and cortical infarction</title><p>CAA-related cerebral hypoperfusion or occlusive small-vessel disease may cause progressive white matter lesions and cortical microinfarcts. Patients with CAA-related ICH exhibit occipital dominant white matter hyperintensities (WMHs) on MRI (<xref ref-type="fig" rid="F4">Figure 4D</xref>), compatible with predilection of CAA pathology for posterior brain regions.<xref rid="B50" ref-type="bibr">50</xref> A posterior distribution of WMH on MRI is associated with the presence of CAA pathology.<xref rid="B51" ref-type="bibr">51</xref> Amyloid burden in non-demented CAA subjects correlated with WMH volumes.<xref rid="B52" ref-type="bibr">52</xref> Acute or subacute subclinical ischemic infarcts are common in CAA-related ICH.<xref rid="B53" ref-type="bibr">53</xref>,<xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B55" ref-type="bibr">55</xref> As a result of the difficulty in detection (see below), CAA as a cause of cortical microinfarcts is underrecognized.</p></sec><sec><title>Dementia</title><p>CAA with hemorrhagic/ischemic vascular lesions or AD pathology may be associated with dementia during its clinical course,<xref rid="B56" ref-type="bibr">56</xref> although dementia is found only in a subgroup of patients with CAA-related ICH at the onset of the initial ICH.<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B57" ref-type="bibr">57</xref> Dementia was noted in 74% of individuals with severe CAA at autopsy.<xref rid="B56" ref-type="bibr">56</xref> Moderate-to-very severe CAA is associated with impaired performance in specific cognitive domains, most notably perceptual speed, which is separate from the effect of AD pathology.<xref rid="B58" ref-type="bibr">58</xref></p></sec><sec><title>CAA-related inflammation</title><p>CAA is commonly associated with immune reactions of monocyte/macrophage-lineage cells.<xref rid="B59" ref-type="bibr">59</xref> CAA can be accompanied by marked inflammation (CAA-related inflammation/angiitis), presenting with subacute leukoencephalopathy that is responsive to immunosuppressive therapies.<xref rid="B59" ref-type="bibr">59</xref>,<xref rid="B60" ref-type="bibr">60</xref>,<xref rid="B61" ref-type="bibr">61</xref>,<xref rid="B62" ref-type="bibr">62</xref>,<xref rid="B63" ref-type="bibr">63</xref> The clinical symptoms include subacute cognitive impairment or seizure, which are different from those of hemorrhagic stroke in noninflammatory CAA. Inflammatory CAA is also characterized by asymmetric T2-hyperintense white matter lesions on MRI.<xref rid="B59" ref-type="bibr">59</xref>,<xref rid="B60" ref-type="bibr">60</xref>,<xref rid="B61" ref-type="bibr">61</xref>,<xref rid="B62" ref-type="bibr">62</xref>,<xref rid="B63" ref-type="bibr">63</xref> CAA-related inflammation is associated with an increase in anti-A&#x003b2; antibodies in cerebrospinal fluid (CSF).<xref rid="B64" ref-type="bibr">64</xref>,<xref rid="B65" ref-type="bibr">65</xref> CAA-related inflammation/angiitis shares pathophysiology with amyloid-related imaging abnormalities (ARIA) induced by A&#x003b2; immunotherapies, as discussed below.</p></sec></sec><sec><title>Biomarkers and diagnosis</title><sec><title>Imaging markers</title><sec><title>CT/MRI</title><p>Cranial CT is an option for macrohemorrhages; however, sensitive MR imaging techniques, such as gradient-echo T2<sup>*</sup> imaging and susceptibility-weighted imaging, are useful for detecting microhemorrhages and cSS.<xref rid="B66" ref-type="bibr">66</xref> A posterior distribution of WMH is a possible marker of CAA.<xref rid="B51" ref-type="bibr">51</xref> Although acute or subacute cortical or subcortical infarctions can be recognized in CAA on diffusion-weighted images,<xref rid="B53" ref-type="bibr">53</xref> cortical microinfarcts are often undetected on MRI because of their limited size.<xref rid="B31" ref-type="bibr">31</xref> Ultra-high strength clinical MR scanners with a higher spatial resolution may enable their detection.<xref rid="B67" ref-type="bibr">67</xref> CT angiography spot signs, suggestive of an acute bleeding process, are associated with warfarin use and ICH volume in both CAA-related lobar ICH and arteriolosclerotic deep ICH.<xref rid="B68" ref-type="bibr">68</xref> Enlarged perivascular spaces in the centrum semiovale are associated with CAA, suggesting an imaging marker for CAA.<xref rid="B69" ref-type="bibr">69</xref>,<xref rid="B70" ref-type="bibr">70</xref>,<xref rid="B71" ref-type="bibr">71</xref></p></sec><sec><title>Functional imaging</title><p>Impaired vascular reactivity in response to visual stimulation or a visual task in CAA was reported in studies with transcranial Doppler ultrasound and functional MRI, consistent with greater distribution of CAA in the occipital lobe.<xref rid="B72" ref-type="bibr">72</xref>,<xref rid="B73" ref-type="bibr">73</xref>,<xref rid="B74" ref-type="bibr">74</xref></p></sec></sec><sec><title>Amyloid PET</title><p>Amyloid imaging with the PET ligand, PiB, revealed an increase of PiB binding that often shows greater occipital uptake in CAA-related ICH (<xref ref-type="fig" rid="F5">Figure 5</xref>).<xref rid="B75" ref-type="bibr">75</xref>,<xref rid="B76" ref-type="bibr">76</xref>,<xref rid="B77" ref-type="bibr">77</xref> Microhemorrhages are associated with PiB retention,<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref> and new CAA-related hemorrhages preferentially occur at sites of PiB retention.<xref rid="B35" ref-type="bibr">35</xref> As a frequent occurrence of high PiB uptake in healthy elderly individuals reflects incipient AD, PiB PET has low specificity for CAA; however, a negative PiB scan rules out CAA with excellent sensitivity.<xref rid="B78" ref-type="bibr">78</xref> Amyloid imaging with such PET ligands as PiB cannot discriminate vascular from parenchymal deposition or A&#x003b2; from other amyloid proteins; reagents specific for vascular A&#x003b2; deposition are favorable candidates for amyloid imaging specific for A&#x003b2;-type CAA.<xref rid="B79" ref-type="bibr">79</xref></p></sec><sec><title>Biochemical markers</title><p>A significant decrease in cerebrospinal fluid (CSF) levels of A&#x003b2;40 as well as A&#x003b2;42 was reported in patients with probable CAA, which suggests trapping of A&#x003b2;40 and A&#x003b2;42 in the cerebral vasculature. Furthermore, CSF levels of total tau and phosphorylated tau are higher in patients with probable CAA than in controls, but lower than in AD.<xref rid="B80" ref-type="bibr">80</xref>,<xref rid="B81" ref-type="bibr">81</xref> It was reported that patients with CAA-related ICH exhibit higher plasma levels of A&#x003b2;42, A&#x003b2;40, and specific A&#x003b2; fragments.<xref rid="B82" ref-type="bibr">82</xref> The presence of anti-A&#x003b2; autoantibodies in CSF is a marker of CAA-related inflammation.<xref rid="B64" ref-type="bibr">64</xref>,<xref rid="B65" ref-type="bibr">65</xref></p></sec><sec><title>Diagnosis</title><p>The Boston criteria were proposed for the diagnosis of CAA-related ICH (<xref ref-type="table" rid="T2">Table 2</xref>), and high diagnostic accuracy was reported with a small pathologic series.<xref rid="B83" ref-type="bibr">83</xref> As hypertension may cause lobar ICH,<xref rid="B23" ref-type="bibr">23</xref> exclusion of advanced hypertension may increase the specificity of the diagnosis of CAA-related ICH; however, the diagnostic sensitivity is decreased,<xref rid="B9" ref-type="bibr">9</xref> because CAA may coexist with hypertension.</p><p>When cSS was incorporated into the classic Boston criteria (the modified Boston criteria) (<xref ref-type="table" rid="T2">Table 2</xref>), the sensitivity increased from 89.5% to 94.7%, and the specificity was 81.2% for both the classic and modified criteria.<xref rid="B32" ref-type="bibr">32</xref></p></sec></sec><sec><title>Current treatment and prognosis</title><p>Currently, no disease-modifying therapies are available for CAA. As for neurosurgery for CAA-related ICH, uncontrollable peri- and post-operative hemorrhages have been reported previously; however, recent studies suggest that neurosurgical procedures, especially hematoma evacuation, can be performed more safely than previously expected.<xref rid="B84" ref-type="bibr">84</xref> In our study involving a nationwide survey in Japan,<xref rid="B9" ref-type="bibr">9</xref> neurosurgical procedures were performed without uncontrollable intra-operative or post-operative hemorrhage in 97.1% of patients. CAA-related lobar ICH recurred in 31.7% of patients during the average 35.3-month follow-up period. The mean interval between ICHs was 11.3 months and the case fatality rate was 12.2% at 1 month and 19.5% at 12 months after initial ICH. Subacute leukoencephalopathy associated with CAA-related inflammation or angiitis was reported to respond to immunosuppressive treatment.<xref rid="B61" ref-type="bibr">61</xref>,<xref rid="B62" ref-type="bibr">62</xref>,<xref rid="B63" ref-type="bibr">63</xref></p></sec></sec><sec><title>Risk factors of CAA and CAA-related disorders</title><p>Aging and AD are established risk factors of CAA;<xref rid="B5" ref-type="bibr">5</xref> besides these, genetic and non-genetic risk factors have been reported for CAA and CAA-related disorders.</p><sec><title>Genetic risk factors</title><sec><title>Apolipoprotein E gene</title><p>In addition to hereditary cases of AD/CAA associated with mutations of the A&#x003b2;PP or presenilin genes [see review<xref rid="B5" ref-type="bibr">5</xref>], the ApoE gene (<italic>ApoE</italic>) has been reported to be risk factor for sporadic CAA as well as AD; the &#x003b5;4 allele for CAA itself, and the &#x003b5;2 allele for CAA-related ICH<xref rid="B85" ref-type="bibr">85</xref>,<xref rid="B86" ref-type="bibr">86</xref>,<xref rid="B87" ref-type="bibr">87</xref> and hematoma expansion.<xref rid="B88" ref-type="bibr">88</xref> Carriers of the <italic>ApoE</italic> &#x003b5;2 or &#x003b5;4 allele, particularly, of the <italic>ApoE</italic> &#x003b5;2/&#x003b5;4 genotype were associated with early recurrence of lobar ICH in patients who survived a lobar ICH.<xref rid="B89" ref-type="bibr">89</xref> The <italic>ApoE</italic> &#x003b5;4 allele constitutes a risk factor for capillary CAA (CAA-Type 1),<xref rid="B11" ref-type="bibr">11</xref> CAA-related inflammation,<xref rid="B63" ref-type="bibr">63</xref> and brain microhemorrhages.<xref rid="B90" ref-type="bibr">90</xref> Furthermore, <italic>ApoE</italic> &#x003b5;2 was overrepresented in patients with cSS.<xref rid="B41" ref-type="bibr">41</xref> The presence of CAA in head injury cases was significantly associated with the <italic>ApoE</italic> &#x003b5;4 allele, suggesting an interaction between gene and environment in the development of CAA.<xref rid="B91" ref-type="bibr">91</xref></p></sec><sec><title>Other genetic factors</title><p>Transforming growth factor (TGF)-&#x003b2;1 is another CAA-related gene reported by more than one research group.<xref rid="B92" ref-type="bibr">92</xref>,<xref rid="B93" ref-type="bibr">93</xref> In addition, CAA was reported to be associated with other gene polymorphisms, including the presenilin 1 (PS1), &#x003b1;1-antichymotrypsin (ACT), neprilysin, low-density lipoprotein-receptor related protein (LRP-1), and angiotensin-converting enzyme (ACE) genes.<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B94" ref-type="bibr">94</xref>,<xref rid="B95" ref-type="bibr">95</xref>,<xref rid="B96" ref-type="bibr">96</xref>,<xref rid="B97" ref-type="bibr">97</xref>,<xref rid="B98" ref-type="bibr">98</xref>,<xref rid="B99" ref-type="bibr">99</xref>,<xref rid="B100" ref-type="bibr">100</xref> Furthermore, a CR1 gene polymorphism, reported to increase the risk of AD, was also reported to be associated with increased risk of CAA-ICH and CAA.<xref rid="B101" ref-type="bibr">101</xref></p></sec></sec><sec><title>Non-genetic risk factors</title><sec><title>Hypertension</title><p>Lowering of blood pressure reduced the risk of CAA-related ICH, suggesting that high blood pressure could be a factor inducing ICH in patients with CAA.<xref rid="B102" ref-type="bibr">102</xref> Hypertension could contribute to progression of CAA-associated vasculopathies, particularly fibrinoid necrosis, leading to the development of CAA-related ICH. It was reported that the prevalence of hypertension was significantly higher in autopsy-confirmed CAA patients with ICH than in those without ICH, suggesting a role for hypertension in the development of CAA-related ICH.<xref rid="B13" ref-type="bibr">13</xref></p></sec><sec><title>Thrombolytic, anticoagulation, and antiplatelet therapies</title><p>There is increasing evidence that CAA could be a risk factor for ICH with thrombolytic therapies for acute myocardial infarction, pulmonary embolism, or ischemic stroke, and for ICH with warfarin therapies.<xref rid="B103" ref-type="bibr">103</xref>,<xref rid="B104" ref-type="bibr">104</xref> Thrombolytic or anticoagulation therapies in patients with micorhemorrhages are a potential risk factor for ICH.<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B105" ref-type="bibr">105</xref>,<xref rid="B106" ref-type="bibr">106</xref> The <italic>ApoE</italic> &#x003b5;2 and &#x003b5;4 alleles were reported as strong risk factors for lobar warfarin-related ICH; this association was considered to be mediated by the effect of <italic>ApoE</italic> &#x003b5; variants on CAA.<xref rid="B107" ref-type="bibr">107</xref> The use of anti-platelet drugs, such as aspirin, is associated with the presence of microhemorrhages, and with strictly lobar microhemorrhages suggestive of CAA.<xref rid="B108" ref-type="bibr">108</xref> In a systematic review of clinical trials with aspirin in AD, ICH was noted in 3.2% of patients in the aspirin group, but in 0% of the control group, suggesting that aspirin use in AD might increase the risk of ICH. A possible explanation for the increased risk of ICH could be CAA in AD.<xref rid="B109" ref-type="bibr">109</xref></p></sec><sec><title>Anti-amyloid therapies</title><p>Clinical and experimental studies of A&#x003b2; immunotherapies for AD have reported CAA-related complications. In clinical trials with A&#x003b2;42 immunization for AD (AN1792, Elan), immunized patients showed a significantly greater frequency of CAA, cortical microhemorrhages, and microvascular lesions than unimmunized AD controls, although the longest living had a virtually complete absence of both plaques and CAA.<xref rid="B110" ref-type="bibr">110</xref> A CAA-related macrohemorrhage was reported in an AD patient in phase 2a of AN1792.<xref rid="B111" ref-type="bibr">111</xref> The findings suggest that A&#x003b2; immunization resulted in solubilization of A&#x003b2;42 in plaques, which migrates out of the brain parenchyma via perivascular interstitial drainage pathways, causing an increase in CAA and CAA-related hemorrhages.<xref rid="B110" ref-type="bibr">110</xref> Menigoencephalitis occurred in 6% of patients treated in the AN1792 trial,<xref rid="B111" ref-type="bibr">111</xref> and perivascular infiltration of lymphocytes was observed around vessels with CAA.<xref rid="B112" ref-type="bibr">112</xref> Furthermore, in a phase 2 trial of bapineuzumab, a humanized monoclonal anti-A&#x003b2; antibody, amyloid-related imaging abnormalities (ARIA) were reported: vasogenic edema and sulcal effusions (ARIA-E) in 17%, and microhemorrhages and hemosiderin deposits (ARIA-H) in 47% of the patients with ARIA-E,<xref rid="B113" ref-type="bibr">113</xref> suggesting that A&#x003b2; immunotherapy resulted in changes in permeability and disruption of CAA-affected vessels. Vasogenic edema was noted in 2 of 2,762 patients with AD at the baseline of the clinical trial; findings were compatible with CAA-related inflammation.<xref rid="B114" ref-type="bibr">114</xref> As discussed above, CAA-related inflammation is associated with the presence of anti-A&#x003b2; autoantibodies in CSF.<xref rid="B64" ref-type="bibr">64</xref>,<xref rid="B65" ref-type="bibr">65</xref> Further studies are required to elucidate the link between A&#x003b2; immunotherapy-induced ARIA and CAA-related inflammation.</p></sec></sec></sec><sec><title>Future perspectives of prediction, prevention, and therapies for CAA and CAA-related disorders</title><p>Biomarker findings and risk factors for CAA and CAA-related disorders are summarized in <xref ref-type="table" rid="T3">Table 3</xref>. A number of studies indicate that the presence of one or more biomarkers plus one or more risk factors suggest the future development of CAA-related disorders. Further prospective studies will establish methods for prediction of CAA-related disorders. To develop preventive and therapeutic methods for CAA and CAA-related disorders, their molecular pathogenesis needs to be further elucidated. The molecular pathogenesis of A&#x003b2; deposition in cerebral blood vessels is discussed in detail elsewhere [see review<xref rid="B5" ref-type="bibr">5</xref>].</p><p>CAA is not necessarily associated with CAA-related disorders. The pathogenesis of CAA-related disorders consists of two steps: (1) cerebrovascular amyloid deposition and (2) vascular injury including disruption, occlusion, and permeability changes. The cerebrovascular amyloid deposition (Step 1) is the primary target of prevention and therapy. Anti-amyloid therapies for CAA are under development including ponezumab, a humanized monoclonal antibody that binds specifically to the carboxyl terminus of A&#x003b2;40.<xref rid="B115" ref-type="bibr">115</xref> Ponezumab was originally developed for AD immunotherapy, and an acceptable safety profile has been suggested for ponezumab in clinical trials for AD.<xref rid="B116" ref-type="bibr">116</xref>,<xref rid="B117" ref-type="bibr">117</xref>,<xref rid="B118" ref-type="bibr">118</xref> Currently, ponezumab has been applied to CAA. A phase 2, randomized, double-blind, placebo-controlled trial is ongoing to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponezumab (PF-04360365) in adult patients with probable CAA-related hemorrhages (NCT01821118).<xref rid="B119" ref-type="bibr">119</xref></p><p>Vascular injury secondary to cerebrovascular amyloid deposition (Step 2) is an important target for prevention of CAA-related disorders. Risk factors and pathogenic mechanisms underlying vascular injury leading to CAA-related hemorrhages are discussed below. For CAA-related hemorrhages, several non-genetic risk factors have been reported and it is recommended to avoid them. These include thrombolytic, anticoagulation, and anti-platelet therapies, hypertension, and minor head trauma in patients with positive biomarkers of CAA and CAA-related disorders (<xref ref-type="table" rid="T3">Table 3</xref>). Pathogenic mechanisms underlying the damage and rupture of CAA-affected vessels remain to be determined. Pathologically, severe CAA is associated with vasculopathies including loss of smooth muscle cells, duplication ("double-barrel" lumen), obliterative intimal changes, hyaline degeneration, microaneurysmal dilatation, and fibrinoid necrosis of the vessel walls (<xref ref-type="fig" rid="F1">Figure 1</xref>).<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref> Of these, fibrinoid necrosis, in particular, is closely linked to CAA-related hemorrhage.<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref> In addition, even in cases without obvious inflammation or angiitis, CAA-affected vessels are associated with an increase in and activation of monocyte/macrophage lineage cells representing immune reactions against vascular amyloid deposition,<xref rid="B59" ref-type="bibr">59</xref> which would damage the vessel walls. A&#x003b2; deposits in blood vessel walls may trigger release of inflammatory components, activation of the complement system, oxidative stress, alterations in blood brain barrier permeability, formation of ion-like channels, and cell toxicity.<xref rid="B120" ref-type="bibr">120</xref> The involvement of matrix metalloproteinases in the degradation of extracellular matrix proteins was suggested in an experimental model and in human brains exhibiting CAA-related ICH.<xref rid="B121" ref-type="bibr">121</xref>,<xref rid="B122" ref-type="bibr">122</xref> Soluble A&#x003b2; oligomers, which are more neurotoxic than insoluble A&#x003b2; fibrils, may damage vessel walls affected with CAA. There is increased evidence that <italic>ApoE</italic> &#x003b5;2 is associated with CAA-related ICH and vessel fragility;<xref rid="B87" ref-type="bibr">87</xref>,<xref rid="B88" ref-type="bibr">88</xref>,<xref rid="B123" ref-type="bibr">123</xref>,<xref rid="B124" ref-type="bibr">124</xref> however, <italic>ApoE</italic>-related pathogenic mechanisms remain to be elucidated. Future preventive/therapeutic strategies for CAA-related hemorrhages should include protection of vessel walls against these factors, as well as the development of anti-amyloid therapies for CAA.</p></sec></body><back><ack><title>Acknowledgements</title><p>The study was supported in part by a grant from the Amyloidosis Research Committee from the Ministry of Health, Labor and Welfare, Japan, and by the SENSHIN Medical Research Foundation, Japan. The author is grateful to Ms. Etsuko Tsujiguchi for her excellent secretarial work.</p></ack><fn-group><fn fn-type="conflict"><p>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholz</surname><given-names>W</given-names></name></person-group><article-title>Studien zur Pathologie der Hirngef&#x000e4;&#x000df;e II. Die drusige Entartung der Hirnarterien und Kapillaren</article-title><source>Z ges Neurol Psychiat</source><year>1938</year><volume>162</volume><fpage>694</fpage><lpage>715</lpage></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surbek</surname><given-names>B</given-names></name></person-group><article-title>L'angiopathie dyshorique (Morel) de l'&#x000e9;corce c&#x000e9;r&#x000e9;brale</article-title><source>Acta Neuropathol</source><year>1961</year><volume>1</volume><fpage>168</fpage><lpage>197</lpage></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pantelakis</surname><given-names>S</given-names></name></person-group><article-title>Un type particulier d'angiopathie s&#x000e9;nile du syst&#x000e8;me nerveux central: l'angiopathice congophile. Topographie et fr&#x000e9;quence</article-title><source>Mschr Psychiatr Neurol</source><year>1954</year><volume>128</volume><fpage>219</fpage><lpage>256</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinters</surname><given-names>HV</given-names></name></person-group><article-title>Cerebral amyloid angiopathy. A critical review</article-title><source>Stroke</source><year>1987</year><volume>18</volume><fpage>311</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">3551211</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Naiki</surname><given-names>H</given-names></name></person-group><article-title>Cerebral amyloid angiopathy</article-title><source>Prog Mol Biol Transl Sci</source><year>2012</year><volume>51</volume><fpage>41</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">22482447</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Tsukagoshi</surname><given-names>H</given-names></name><name><surname>Otomo</surname><given-names>E</given-names></name><name><surname>Hayakawa</surname><given-names>M</given-names></name></person-group><article-title>Cerebral amyloid angiopathy in the aged</article-title><source>J Neurol</source><year>1987</year><volume>234</volume><fpage>371</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">3655840</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuda</surname><given-names>J</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Ueda</surname><given-names>K</given-names></name><name><surname>Omae</surname><given-names>T</given-names></name></person-group><article-title>Autopsy study of incidence and distribution of cerebral amyloid angiopathy in Hisayama, Japan</article-title><source>Stroke</source><year>1988</year><volume>19</volume><fpage>205</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">3344537</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M</given-names></name></person-group><article-title>Risk factors for cerebral amyloid angiopathy in the elderly</article-title><source>Ann N Y Acad Sci</source><year>2002</year><volume>977</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">12480732</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirohata</surname><given-names>M</given-names></name><name><surname>Yoshita</surname><given-names>M</given-names></name><name><surname>Ishida</surname><given-names>C</given-names></name><name><surname>Ikeda</surname><given-names>SI</given-names></name><name><surname>Tamaoka</surname><given-names>A</given-names></name><name><surname>Kuzuhara</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical features of non-hypertensive lobar intracerebral hemorrhage related to cerebral amyloid angiopathy</article-title><source>Eur J Neurol</source><year>2010</year><volume>17</volume><fpage>823</fpage><lpage>829</lpage><pub-id pub-id-type="pmid">20158508</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Yamazaki</surname><given-names>T</given-names></name><name><surname>Lemere</surname><given-names>CA</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study</article-title><source>Am J Pathol</source><year>1992</year><volume>141</volume><fpage>249</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">1632466</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Ghebremedhin</surname><given-names>E</given-names></name><name><surname>Rub</surname><given-names>U</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name></person-group><article-title>Two types of sporadic cerebral amyloid angiopathy</article-title><source>J Neuropathol Exp Neurol</source><year>2002</year><volume>61</volume><fpage>282</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">11895043</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandybur</surname><given-names>TI</given-names></name></person-group><article-title>Cerebral amyloid angiopathy: the vascular pathology and complications</article-title><source>J Neuropathol Exp Neurol</source><year>1986</year><volume>45</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">3941328</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vonsattel</surname><given-names>JP</given-names></name><name><surname>Myers</surname><given-names>RH</given-names></name><name><surname>Hedley-Whyte</surname><given-names>ET</given-names></name><name><surname>Ropper</surname><given-names>AH</given-names></name><name><surname>Bird</surname><given-names>ED</given-names></name><name><surname>Richardson</surname><given-names>EP</given-names><suffix>Jr</suffix></name></person-group><article-title>Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study</article-title><source>Ann Neurol</source><year>1991</year><volume>30</volume><fpage>637</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">1763890</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Otomo</surname><given-names>E</given-names></name><name><surname>Hayakawa</surname><given-names>M</given-names></name><name><surname>Miyatake</surname><given-names>T</given-names></name></person-group><article-title>Computer-assisted three-dimensional image analysis of cerebral amyloid angiopathy</article-title><source>Stroke</source><year>1993</year><volume>24</volume><fpage>1857</fpage><lpage>1864</lpage><pub-id pub-id-type="pmid">8248968</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prelli</surname><given-names>F</given-names></name><name><surname>Castano</surname><given-names>E</given-names></name><name><surname>Glenner</surname><given-names>GG</given-names></name><name><surname>Frangione</surname><given-names>B</given-names></name></person-group><article-title>Differences between vascular and plaque core amyloid in Alzheimer's disease</article-title><source>J Neurochem</source><year>1988</year><volume>51</volume><fpage>648</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">3292706</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Odaka</surname><given-names>A</given-names></name><name><surname>Ishibashi</surname><given-names>Y</given-names></name><name><surname>Kitada</surname><given-names>C</given-names></name><name><surname>Ihara</surname><given-names>Y</given-names></name></person-group><article-title>High tissue content of soluble &#x003b2;1-40 is linked to cerebral amyloid angiopathy</article-title><source>Am J Pathol</source><year>1994</year><volume>145</volume><fpage>452</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">8053502</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weller</surname><given-names>RO</given-names></name><name><surname>Massey</surname><given-names>A</given-names></name><name><surname>Newman</surname><given-names>TA</given-names></name><name><surname>Hutchings</surname><given-names>M</given-names></name><name><surname>Kuo</surname><given-names>YM</given-names></name><name><surname>Roher</surname><given-names>AE</given-names></name></person-group><article-title>Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease</article-title><source>Am J Pathol</source><year>1998</year><volume>153</volume><fpage>725</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">9736023</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M</given-names></name></person-group><article-title>Predicting cerebral amyloid angiopathy-related intracerebral hemorrhages and other cerebrovascular disorders in Alzheimer's disease</article-title><source>Front Neurol</source><year>2012</year><volume>3</volume><fpage>64</fpage><pub-id pub-id-type="pmid">22539931</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samarasekera</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Al-Shahi Salman</surname><given-names>R</given-names></name></person-group><article-title>The association between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysis</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2012</year><volume>83</volume><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">22056966</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meretoja</surname><given-names>A</given-names></name><name><surname>Strbian</surname><given-names>D</given-names></name><name><surname>Putaala</surname><given-names>J</given-names></name><name><surname>Curtze</surname><given-names>S</given-names></name><name><surname>Haapaniemi</surname><given-names>E</given-names></name><name><surname>Mustanoja</surname><given-names>S</given-names></name><etal/></person-group><article-title>SMASH-U: a proposal for etiologic classification of intracerebral hemorrhage</article-title><source>Stroke</source><year>2012</year><volume>43</volume><fpage>2592</fpage><lpage>2597</lpage><pub-id pub-id-type="pmid">22858729</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>SJ</given-names></name><name><surname>Tang</surname><given-names>SC</given-names></name><name><surname>Tsai</surname><given-names>LK</given-names></name><name><surname>Jeng</surname><given-names>JS</given-names></name></person-group><article-title>Pathogenetical subtypes of recurrent intracerebral hemorrhage: designations by SMASH-U classification system</article-title><source>Stroke</source><year>2014</year><volume>45</volume><fpage>2636</fpage><lpage>2642</lpage><pub-id pub-id-type="pmid">25052320</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e9;jot</surname><given-names>Y</given-names></name><name><surname>Cordonnier</surname><given-names>C</given-names></name><name><surname>Durier</surname><given-names>J</given-names></name><name><surname>Aboa-Eboul&#x000e9;</surname><given-names>C</given-names></name><name><surname>Rouaud</surname><given-names>O</given-names></name><name><surname>Giroud</surname><given-names>M</given-names></name></person-group><article-title>Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study</article-title><source>Brain</source><year>2013</year><volume>136</volume><fpage>658</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">23378220</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Hayakawa</surname><given-names>M</given-names></name><name><surname>Otomo</surname><given-names>E</given-names></name><name><surname>Miyatake</surname><given-names>T</given-names></name></person-group><article-title>Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly</article-title><source>J Neurol Sci</source><year>1993</year><volume>116</volume><fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">8336159</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Otomo</surname><given-names>E</given-names></name><name><surname>Hayakawa</surname><given-names>M</given-names></name><name><surname>Miyatake</surname><given-names>T</given-names></name></person-group><article-title>Subarachnoid haemorrhage in the elderly: a necropsy study of the association with cerebral amyloid angiopathy</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1993</year><volume>56</volume><fpage>543</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">8505648</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohshima</surname><given-names>T</given-names></name><name><surname>Endo</surname><given-names>T</given-names></name><name><surname>Nukui</surname><given-names>H</given-names></name><name><surname>Ikeda</surname><given-names>S</given-names></name><name><surname>Allsop</surname><given-names>D</given-names></name><name><surname>Onaya</surname><given-names>T</given-names></name></person-group><article-title>Cerebral amyloid angiopathy as a cause of subarachnoid hemorrhage</article-title><source>Stroke</source><year>1990</year><volume>21</volume><fpage>480</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">2309274</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanyu</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>S</given-names></name><name><surname>Takasaki</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name></person-group><article-title>Cerebral microbleeds in Alzheimer's disease</article-title><source>J Neurol</source><year>2003</year><volume>250</volume><fpage>1496</fpage><lpage>1497</lpage><pub-id pub-id-type="pmid">14673587</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakata-Kudo</surname><given-names>Y</given-names></name><name><surname>Mizuno</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Shiga</surname><given-names>K</given-names></name><name><surname>Yoshikawa</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><etal/></person-group><article-title>Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2006</year><volume>22</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">16645275</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordonnier</surname><given-names>C</given-names></name><name><surname>van der Flier</surname><given-names>WM</given-names></name><name><surname>Sluimer</surname><given-names>JD</given-names></name><name><surname>Leys</surname><given-names>D</given-names></name><name><surname>Bark hof</surname><given-names>F</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name></person-group><article-title>Prevalence and severity of microbleeds in a memory clinic setting</article-title><source>Neurology</source><year>2006</year><volume>66</volume><fpage>1356</fpage><lpage>1360</lpage><pub-id pub-id-type="pmid">16682667</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordonnier</surname><given-names>C</given-names></name><name><surname>Al-Shahi Salman</surname><given-names>R</given-names></name><name><surname>Wardlaw</surname><given-names>J</given-names></name></person-group><article-title>Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting</article-title><source>Brain</source><year>2007</year><volume>130</volume><fpage>1988</fpage><lpage>2003</lpage><pub-id pub-id-type="pmid">17322562</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>JA</given-names></name><name><surname>Sathiyamoorthy</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>FQ</given-names></name><name><surname>Szilagyi</surname><given-names>G</given-names></name><name><surname>Nadkarni</surname><given-names>NK</given-names></name><name><surname>St George-Hyslop</surname><given-names>P</given-names></name><etal/></person-group><article-title>Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study</article-title><source>Arch Neurol</source><year>2008</year><volume>65</volume><fpage>790</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">18541799</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brundel</surname><given-names>M</given-names></name><name><surname>Heringa</surname><given-names>SM</given-names></name><name><surname>de Bresser</surname><given-names>J</given-names></name><name><surname>Koek</surname><given-names>HL</given-names></name><name><surname>Zwanenburg</surname><given-names>JJ</given-names></name><name><surname>Jaap Kappelle</surname><given-names>L</given-names></name><etal/></person-group><article-title>High prevalence of cerebral microbleeds at 7Tesla MRI in patients with early Alzheimer's disease</article-title><source>J Alzheimers Dis</source><year>2012</year><volume>31</volume><fpage>259</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">22531417</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linn</surname><given-names>J</given-names></name><name><surname>Halpin</surname><given-names>A</given-names></name><name><surname>Demaerel</surname><given-names>P</given-names></name><name><surname>Ruhland</surname><given-names>J</given-names></name><name><surname>Giese</surname><given-names>AD</given-names></name><name><surname>Dichgans</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy</article-title><source>Neurology</source><year>2010</year><volume>74</volume><fpage>1346</fpage><lpage>1350</lpage><pub-id pub-id-type="pmid">20421578</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>PA</given-names></name><name><surname>Sirisriro</surname><given-names>R</given-names></name><name><surname>Villemagne</surname><given-names>VL</given-names></name><name><surname>Farquharson</surname><given-names>S</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Rowe</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Cerebral microhemorrhage and brain &#x003b2;-amyloid in aging and Alzheimer disease</article-title><source>Neurology</source><year>2011</year><volume>77</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">21700585</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dierksen</surname><given-names>GA</given-names></name><name><surname>Skehan</surname><given-names>ME</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Jeng</surname><given-names>J</given-names></name><name><surname>Nandigam</surname><given-names>RN</given-names></name><name><surname>Becker</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy</article-title><source>Ann Neurol</source><year>2010</year><volume>68</volume><fpage>545</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">20865701</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurol</surname><given-names>ME</given-names></name><name><surname>Dierksen</surname><given-names>G</given-names></name><name><surname>Betensky</surname><given-names>R</given-names></name><name><surname>Gidicsin</surname><given-names>C</given-names></name><name><surname>Halpin</surname><given-names>A</given-names></name><name><surname>Becker</surname><given-names>A</given-names></name><etal/></person-group><article-title>Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy</article-title><source>Neurology</source><year>2012</year><volume>79</volume><fpage>320</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">22786597</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Etten</surname><given-names>ES</given-names></name><name><surname>Auriel</surname><given-names>E</given-names></name><name><surname>Haley</surname><given-names>KE</given-names></name><name><surname>Ayres</surname><given-names>AM</given-names></name><name><surname>Vashkevich</surname><given-names>A</given-names></name><name><surname>Schwab</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Incidence of symptomatic hemorrhage in patients with lobar microbleeds</article-title><source>Stroke</source><year>2014</year><volume>45</volume><fpage>2280</fpage><lpage>2285</lpage><pub-id pub-id-type="pmid">24947286</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>HH</given-names></name><name><surname>Maia</surname><given-names>LF</given-names></name><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Forster</surname><given-names>BB</given-names></name><name><surname>Martzke</surname><given-names>J</given-names></name><name><surname>Woolfenden</surname><given-names>A</given-names></name></person-group><article-title>Superficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer disease</article-title><source>Stroke</source><year>2008</year><volume>39</volume><fpage>2894</fpage><lpage>2897</lpage><pub-id pub-id-type="pmid">18635858</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Goddeau</surname><given-names>RP</given-names><suffix>Jr</suffix></name><name><surname>Selim</surname><given-names>MH</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Schlaug</surname><given-names>G</given-names></name><name><surname>Alhazzani</surname><given-names>A</given-names></name><etal/></person-group><article-title>Atraumatic convexal subarachnoid hemorrhage: clinical presentation, imaging patterns, and etiologies</article-title><source>Neurology</source><year>2010</year><volume>74</volume><fpage>893</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">20231664</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vernooij</surname><given-names>MW</given-names></name><name><surname>Ikram</surname><given-names>MA</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Krestin</surname><given-names>GP</given-names></name><name><surname>Breteler</surname><given-names>MM</given-names></name><name><surname>van der Lugt</surname><given-names>A</given-names></name></person-group><article-title>Superficial siderosis in the general population</article-title><source>Neurology</source><year>2009</year><volume>73</volume><fpage>202</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">19620607</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charidimou</surname><given-names>A</given-names></name><name><surname>Peeters</surname><given-names>AP</given-names></name><name><surname>J&#x000e4;ger</surname><given-names>R</given-names></name><name><surname>Fox</surname><given-names>Z</given-names></name><name><surname>Vandermeeren</surname><given-names>Y</given-names></name><name><surname>Laloux</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy</article-title><source>Neurology</source><year>2013</year><volume>81</volume><fpage>1666</fpage><lpage>1673</lpage><pub-id pub-id-type="pmid">24107862</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoamanesh</surname><given-names>A</given-names></name><name><surname>Martinez-Ramirez</surname><given-names>S</given-names></name><name><surname>Oliveira-Filho</surname><given-names>J</given-names></name><name><surname>Reijmer</surname><given-names>Y</given-names></name><name><surname>Falcone</surname><given-names>GJ</given-names></name><name><surname>Ayres</surname><given-names>A</given-names></name><etal/></person-group><article-title>Interrelationship of superficial siderosis and microbleeds in cerebral amyloid angiopathy</article-title><source>Neurology</source><year>2014</year><volume>83</volume><fpage>1838</fpage><lpage>1843</lpage><pub-id pub-id-type="pmid">25320098</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linn</surname><given-names>J</given-names></name><name><surname>Wollenweber</surname><given-names>FA</given-names></name><name><surname>Lummel</surname><given-names>N</given-names></name><name><surname>Bochmann</surname><given-names>K</given-names></name><name><surname>Pfefferkorn</surname><given-names>T</given-names></name><name><surname>Gschwendtner</surname><given-names>A</given-names></name><etal/></person-group><article-title>Superficial siderosis is a warning sign for future intracranial hemorrhage</article-title><source>J Neurol</source><year>2013</year><volume>260</volume><fpage>176</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">22820723</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollenweber</surname><given-names>FA</given-names></name><name><surname>Buerger</surname><given-names>K</given-names></name><name><surname>Mueller</surname><given-names>C</given-names></name><name><surname>Ertl-Wagner</surname><given-names>B</given-names></name><name><surname>Malik</surname><given-names>R</given-names></name><name><surname>Dichgans</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevalence of cortical superficial siderosis in patients with cognitive impairment</article-title><source>J Neurol</source><year>2014</year><volume>261</volume><fpage>277</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">24221645</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zonneveld</surname><given-names>HI</given-names></name><name><surname>Goos</surname><given-names>JD</given-names></name><name><surname>Wattjes</surname><given-names>MP</given-names></name><name><surname>Prins</surname><given-names>ND</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>van der Flier</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Prevalence of cortical superficial siderosis in a memory clinic population</article-title><source>Neurology</source><year>2014</year><volume>82</volume><fpage>698</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">24477113</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izenberg</surname><given-names>A</given-names></name><name><surname>Aviv</surname><given-names>RI</given-names></name><name><surname>Demaerschalk</surname><given-names>BM</given-names></name><name><surname>Dodick</surname><given-names>DW</given-names></name><name><surname>Hopyan</surname><given-names>J</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Crescendo transient aura attacks: a transient ischemic attack mimic caused by focal subarachnoid hemorrhage</article-title><source>Stroke</source><year>2009</year><volume>40</volume><fpage>3725</fpage><lpage>3729</lpage><pub-id pub-id-type="pmid">19893001</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beitzke</surname><given-names>M</given-names></name><name><surname>Gattringer</surname><given-names>T</given-names></name><name><surname>Enzinger</surname><given-names>C</given-names></name><name><surname>Wagner</surname><given-names>G</given-names></name><name><surname>Niederkorn</surname><given-names>K</given-names></name><name><surname>Fazekas</surname><given-names>F</given-names></name></person-group><article-title>Clinical presentation, etiology, and long-term prognosis in patients with nontraumatic convexal subarachnoid hemorrhage</article-title><source>Stroke</source><year>2011</year><volume>42</volume><fpage>3055</fpage><lpage>3060</lpage><pub-id pub-id-type="pmid">21921284</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charidimou</surname><given-names>A</given-names></name><name><surname>Peeters</surname><given-names>A</given-names></name><name><surname>Fox</surname><given-names>Z</given-names></name><name><surname>Gregoire</surname><given-names>SM</given-names></name><name><surname>Vandermeeren</surname><given-names>Y</given-names></name><name><surname>Laloux</surname><given-names>P</given-names></name><etal/></person-group><article-title>Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis</article-title><source>Stroke</source><year>2012</year><volume>43</volume><fpage>2324</fpage><lpage>2330</lpage><pub-id pub-id-type="pmid">22798323</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apoil</surname><given-names>M</given-names></name><name><surname>Cogez</surname><given-names>J</given-names></name><name><surname>Dubuc</surname><given-names>L</given-names></name><name><surname>Bataille</surname><given-names>M</given-names></name><name><surname>de la Sayette</surname><given-names>V</given-names></name><name><surname>Touz&#x000e9;</surname><given-names>E</given-names></name><etal/></person-group><article-title>Focal cortical subarachnoid hemorrhage revealed by recurrent paresthesias: a clinico-radiological syndrome strongly associated with cerebral amyloid angiopathy</article-title><source>Cerebrovasc Dis</source><year>2013</year><volume>36</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">24029731</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charidimou</surname><given-names>A</given-names></name><name><surname>Baron</surname><given-names>JC</given-names></name><name><surname>Werring</surname><given-names>DJ</given-names></name></person-group><article-title>Transient focal neurological episodes, cerebral amyloid angiopathy, and intracerebral hemorrhage risk: looking beyond TIAs</article-title><source>Int J Stroke</source><year>2013</year><volume>8</volume><fpage>105</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">23336261</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>YC</given-names></name><name><surname>Chabriat</surname><given-names>H</given-names></name><name><surname>Godin</surname><given-names>O</given-names></name><name><surname>Dufouil</surname><given-names>C</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Distribution of white matter hyperintensity in cerebral hemorrhage and healthy aging</article-title><source>J Neurol</source><year>2012</year><volume>259</volume><fpage>530</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">21877206</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thanprasertsuk</surname><given-names>S</given-names></name><name><surname>Martinez-Ramirez</surname><given-names>S</given-names></name><name><surname>Pontes-Neto</surname><given-names>OM</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Ayres</surname><given-names>A</given-names></name><name><surname>Reed</surname><given-names>A</given-names></name><etal/></person-group><article-title>Posterior white matter disease distribution as a predictor of amyloid angiopathy</article-title><source>Neurology</source><year>2014</year><volume>83</volume><fpage>794</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">25063759</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurol</surname><given-names>ME</given-names></name><name><surname>Viswanathan</surname><given-names>A</given-names></name><name><surname>Gidicsin</surname><given-names>C</given-names></name><name><surname>Hedden</surname><given-names>T</given-names></name><name><surname>Martinez-Ramirez</surname><given-names>S</given-names></name><name><surname>Dumas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study</article-title><source>Ann Neurol</source><year>2013</year><volume>73</volume><fpage>529</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">23424091</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimberly</surname><given-names>WT</given-names></name><name><surname>Gilson</surname><given-names>A</given-names></name><name><surname>Rost</surname><given-names>NS</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Viswanathan</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>EE</given-names></name><etal/></person-group><article-title>Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy</article-title><source>Neurology</source><year>2009</year><volume>72</volume><fpage>1230</fpage><lpage>1235</lpage><pub-id pub-id-type="pmid">19349602</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregoire</surname><given-names>SM</given-names></name><name><surname>Charidimou</surname><given-names>A</given-names></name><name><surname>Gadapa</surname><given-names>N</given-names></name><name><surname>Dolan</surname><given-names>E</given-names></name><name><surname>Antoun</surname><given-names>N</given-names></name><name><surname>Peeters</surname><given-names>A</given-names></name><etal/></person-group><article-title>Acute ischaemic brain lesions in intracerebral haemorrhage: multicentre cross-sectional magnetic resonance imaging study</article-title><source>Brain</source><year>2011</year><volume>134</volume><fpage>2376</fpage><lpage>2386</lpage><pub-id pub-id-type="pmid">21841203</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallat</surname><given-names>W</given-names></name><name><surname>Maundrell</surname><given-names>A</given-names></name><name><surname>Leyden</surname><given-names>J</given-names></name><name><surname>Kleinig</surname><given-names>TJ</given-names></name></person-group><article-title>Cerebral amyloid angiopathy causing cortical microinfarction</article-title><source>J Clin Neurosci</source><year>2013</year><volume>20</volume><fpage>1802</fpage><lpage>1804</lpage><pub-id pub-id-type="pmid">23871452</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Suematsu</surname><given-names>N</given-names></name><name><surname>Otomo</surname><given-names>E</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name></person-group><article-title>Vascular variant of Alzheimer's disease characterized by severe plaque-like beta protein angiopathy</article-title><source>Dement Geriatr Cogn Disord</source><year>1997</year><volume>8</volume><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">9137894</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordonnier</surname><given-names>C</given-names></name><name><surname>Leys</surname><given-names>D</given-names></name><name><surname>Dumont</surname><given-names>F</given-names></name><name><surname>Deramecourt</surname><given-names>V</given-names></name><name><surname>Bordet</surname><given-names>R</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><etal/></person-group><article-title>What are the causes of pre-existing dementia in patients with intracerebral haemorrhages?</article-title><source>Brain</source><year>2010</year><volume>133</volume><fpage>3281</fpage><lpage>3289</lpage><pub-id pub-id-type="pmid">20852266</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvanitakis</surname><given-names>Z</given-names></name><name><surname>Leurgans</surname><given-names>SE</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wilson</surname><given-names>RS</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name></person-group><article-title>Cerebral amyloid angiopathy pathology and cognitive domains in older persons</article-title><source>Ann Neurol</source><year>2011</year><volume>69</volume><fpage>320</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">21387377</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Shintaku</surname><given-names>M</given-names></name><name><surname>Kawamura</surname><given-names>J</given-names></name><name><surname>Jensson</surname><given-names>O</given-names></name><name><surname>Thorsteinsson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Immune reactions associated with cerebral amyloid angiopathy</article-title><source>Stroke</source><year>1996</year><volume>27</volume><fpage>1155</fpage><lpage>1162</lpage><pub-id pub-id-type="pmid">8685920</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>U</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Krakauer</surname><given-names>JW</given-names></name><name><surname>Khandji</surname><given-names>AG</given-names></name><name><surname>Chin</surname><given-names>SS</given-names></name><name><surname>Elkind</surname><given-names>MS</given-names></name></person-group><article-title>Reversible leukoencephalopathy associated with cerebral amyloid angiopathy</article-title><source>Neurology</source><year>2004</year><volume>62</volume><fpage>494</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">14872042</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eng</surname><given-names>JA</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Choi</surname><given-names>K</given-names></name><name><surname>Rebeck</surname><given-names>GW</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name></person-group><article-title>Clinical manifestations of cerebral amyloid angiopathy-related inflammation</article-title><source>Ann Neurol</source><year>2004</year><volume>55</volume><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">14755729</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scolding</surname><given-names>NJ</given-names></name><name><surname>Joseph</surname><given-names>F</given-names></name><name><surname>Kirby</surname><given-names>PA</given-names></name><name><surname>Mazanti</surname><given-names>I</given-names></name><name><surname>Gray</surname><given-names>F</given-names></name><name><surname>Mikol</surname><given-names>J</given-names></name><etal/></person-group><article-title>A&#x003b2;-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy</article-title><source>Brain</source><year>2005</year><volume>128</volume><fpage>500</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">15659428</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinnecom</surname><given-names>C</given-names></name><name><surname>Lev</surname><given-names>MH</given-names></name><name><surname>Wendell</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>EE</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Course of cerebral amyloid angiopathy-related inflammation</article-title><source>Neurology</source><year>2007</year><volume>68</volume><fpage>1411</fpage><lpage>1416</lpage><pub-id pub-id-type="pmid">17452586</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiFrancesco</surname><given-names>JC</given-names></name><name><surname>Brioschi</surname><given-names>M</given-names></name><name><surname>Brighina</surname><given-names>L</given-names></name><name><surname>Ruffmann</surname><given-names>C</given-names></name><name><surname>Saracchi</surname><given-names>E</given-names></name><name><surname>Costantino</surname><given-names>G</given-names></name><etal/></person-group><article-title>Anti-A&#x003b2; autoantibodies in the CSF of a patient with CAA-related inflammation: a case report</article-title><source>Neurology</source><year>2011</year><volume>76</volume><fpage>842</fpage><lpage>844</lpage><pub-id pub-id-type="pmid">21357837</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piazza</surname><given-names>F</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name><name><surname>Savoiardo</surname><given-names>M</given-names></name><name><surname>Gardinetti</surname><given-names>M</given-names></name><name><surname>Chiapparini</surname><given-names>L</given-names></name><name><surname>Raicher</surname><given-names>I</given-names></name><etal/></person-group><article-title>Anti-amyloid &#x003b2; autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies</article-title><source>Ann Neurol</source><year>2013</year><volume>73</volume><fpage>449</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">23625526</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandigam</surname><given-names>RN</given-names></name><name><surname>Viswanathan</surname><given-names>A</given-names></name><name><surname>Delgado</surname><given-names>P</given-names></name><name><surname>Skehan</surname><given-names>ME</given-names></name><name><surname>Smith</surname><given-names>EE</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><etal/></person-group><article-title>MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength</article-title><source>AJNR Am J Neuroradiol</source><year>2009</year><volume>30</volume><fpage>338</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">19001544</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ii</surname><given-names>Y</given-names></name><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Kida</surname><given-names>H</given-names></name><name><surname>Matsuo</surname><given-names>K</given-names></name><name><surname>Shindo</surname><given-names>A</given-names></name><name><surname>Taniguchi</surname><given-names>A</given-names></name><etal/></person-group><article-title>In vivo detection of cortical microinfarcts on ultrahigh-field MRI</article-title><source>J Neuroimaging</source><year>2013</year><volume>23</volume><fpage>28</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">22607584</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radmanesh</surname><given-names>F</given-names></name><name><surname>Falcone</surname><given-names>GJ</given-names></name><name><surname>Anderson</surname><given-names>CD</given-names></name><name><surname>Battey</surname><given-names>TW</given-names></name><name><surname>Ayres</surname><given-names>AM</given-names></name><name><surname>Vashkevich</surname><given-names>A</given-names></name><etal/></person-group><article-title>Risk factors for computed tomography angiography spot sign in deep and lobar intracerebral hemorrhage are shared</article-title><source>Stroke</source><year>2014</year><volume>45</volume><fpage>1833</fpage><lpage>1835</lpage><pub-id pub-id-type="pmid">24876264</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charidimou</surname><given-names>A</given-names></name><name><surname>Meegahage</surname><given-names>R</given-names></name><name><surname>Fox</surname><given-names>Z</given-names></name><name><surname>Peeters</surname><given-names>A</given-names></name><name><surname>Vandermeeren</surname><given-names>Y</given-names></name><name><surname>Laloux</surname><given-names>P</given-names></name><etal/></person-group><article-title>Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2013</year><volume>84</volume><fpage>624</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">23412074</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charidimou</surname><given-names>A</given-names></name><name><surname>Jaunmuktane</surname><given-names>Z</given-names></name><name><surname>Baron</surname><given-names>JC</given-names></name><name><surname>Burnell</surname><given-names>M</given-names></name><name><surname>Varlet</surname><given-names>P</given-names></name><name><surname>Peeters</surname><given-names>A</given-names></name><etal/></person-group><article-title>White matter perivascular spaces: an MRI marker in pathology-proven cerebral amyloid angiopathy?</article-title><source>Neurology</source><year>2014</year><volume>82</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">24285616</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charidimou</surname><given-names>A</given-names></name><name><surname>J&#x000e4;ger</surname><given-names>RH</given-names></name><name><surname>Peeters</surname><given-names>A</given-names></name><name><surname>Vandermeeren</surname><given-names>Y</given-names></name><name><surname>Laloux</surname><given-names>P</given-names></name><name><surname>Baron</surname><given-names>JC</given-names></name><etal/></person-group><article-title>White matter perivascular spaces are related to cortical superficial siderosis in cerebral amyloid angiopathy</article-title><source>Stroke</source><year>2014</year><volume>45</volume><fpage>2930</fpage><lpage>2935</lpage><pub-id pub-id-type="pmid">25116879</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>EE</given-names></name><name><surname>Vijayappa</surname><given-names>M</given-names></name><name><surname>Lima</surname><given-names>F</given-names></name><name><surname>Delgado</surname><given-names>P</given-names></name><name><surname>Wendell</surname><given-names>L</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><etal/></person-group><article-title>Impaired visual evoked flow velocity response in cerebral amyloid angiopathy</article-title><source>Neurology</source><year>2008</year><volume>71</volume><fpage>1424</fpage><lpage>1430</lpage><pub-id pub-id-type="pmid">18955685</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumas</surname><given-names>A</given-names></name><name><surname>Dierksen</surname><given-names>GA</given-names></name><name><surname>Gurol</surname><given-names>ME</given-names></name><name><surname>Halpin</surname><given-names>A</given-names></name><name><surname>Martinez-Ramirez</surname><given-names>S</given-names></name><name><surname>Schwab</surname><given-names>K</given-names></name><etal/></person-group><article-title>Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy</article-title><source>Ann Neurol</source><year>2012</year><volume>72</volume><fpage>76</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">22829269</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peca</surname><given-names>S</given-names></name><name><surname>McCreary</surname><given-names>CR</given-names></name><name><surname>Donaldson</surname><given-names>E</given-names></name><name><surname>Kumarpillai</surname><given-names>G</given-names></name><name><surname>Shobha</surname><given-names>N</given-names></name><name><surname>Sanchez</surname><given-names>K</given-names></name><etal/></person-group><article-title>Neurovascular decoupling is associated with severity of cerebral amyloid angiopathy</article-title><source>Neurology</source><year>2013</year><volume>81</volume><fpage>1659</fpage><lpage>1665</lpage><pub-id pub-id-type="pmid">24097810</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Gregas</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>JA</given-names></name><name><surname>Kinnecom</surname><given-names>C</given-names></name><name><surname>Salat</surname><given-names>DH</given-names></name><name><surname>Moran</surname><given-names>EK</given-names></name><etal/></person-group><article-title>Imaging of amyloid burden and distribution in cerebral amyloid angiopathy</article-title><source>Ann Neurol</source><year>2007</year><volume>62</volume><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">17683091</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacskai</surname><given-names>BJ</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Freeman</surname><given-names>SH</given-names></name><name><surname>Raymond</surname><given-names>SB</given-names></name><name><surname>Augustinack</surname><given-names>JC</given-names></name><name><surname>Johnson</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report</article-title><source>Arch Neurol</source><year>2007</year><volume>64</volume><fpage>431</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">17353389</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ly</surname><given-names>JV</given-names></name><name><surname>Donnan</surname><given-names>GA</given-names></name><name><surname>Villemagne</surname><given-names>VL</given-names></name><name><surname>Zavala</surname><given-names>JA</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>O'Keefe</surname><given-names>G</given-names></name><etal/></person-group><article-title>11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage</article-title><source>Neurology</source><year>2010</year><volume>74</volume><fpage>487</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">20142615</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>JC</given-names></name><name><surname>Farid</surname><given-names>K</given-names></name><name><surname>Dolan</surname><given-names>E</given-names></name><name><surname>Turc</surname><given-names>G</given-names></name><name><surname>Marrapu</surname><given-names>ST</given-names></name><name><surname>O'Brien</surname><given-names>E</given-names></name><etal/></person-group><article-title>Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage</article-title><source>J Cereb Blood Flow Metab</source><year>2014</year><volume>34</volume><fpage>753</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">24619277</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutgers</surname><given-names>KS</given-names></name><name><surname>van Remoortere</surname><given-names>A</given-names></name><name><surname>van Buchem</surname><given-names>MA</given-names></name><name><surname>Verrips</surname><given-names>CT</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name><name><surname>Bacskai</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Differential recognition of vascular and parenchymal beta amyloid deposition</article-title><source>Neurobiol Aging</source><year>2011</year><volume>32</volume><fpage>1774</fpage><lpage>1783</lpage><pub-id pub-id-type="pmid">20015576</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbeek</surname><given-names>MM</given-names></name><name><surname>Kremer</surname><given-names>BP</given-names></name><name><surname>Rikkert</surname><given-names>MO</given-names></name><name><surname>Van Domburg</surname><given-names>PH</given-names></name><name><surname>Skehan</surname><given-names>ME</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name></person-group><article-title>Cerebrospinal fluid amyloid &#x003b2;40 is decreased in cerebral amyloid angiopathy</article-title><source>Ann Neurol</source><year>2009</year><volume>66</volume><fpage>245</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">19743453</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renard</surname><given-names>D</given-names></name><name><surname>Castelnovo</surname><given-names>G</given-names></name><name><surname>Wacongne</surname><given-names>A</given-names></name><name><surname>Le Floch</surname><given-names>A</given-names></name><name><surname>Thouvenot</surname><given-names>E</given-names></name><name><surname>Mas</surname><given-names>J</given-names></name><etal/></person-group><article-title>Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria</article-title><source>J Neurol</source><year>2012</year><volume>259</volume><fpage>2429</fpage><lpage>2433</lpage><pub-id pub-id-type="pmid">22576334</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Guillamon</surname><given-names>M</given-names></name><name><surname>Delgado</surname><given-names>P</given-names></name><name><surname>Penalba</surname><given-names>A</given-names></name><name><surname>Rodriguez-Luna</surname><given-names>D</given-names></name><name><surname>Molina</surname><given-names>CA</given-names></name><name><surname>Rovira</surname><given-names>A</given-names></name><etal/></person-group><article-title>Plasma &#x003b2;-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke</article-title><source>Neurodegener Dis</source><year>2012</year><volume>10</volume><fpage>320</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">22261638</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>KA</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Karluk</surname><given-names>D</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name></person-group><article-title>Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria</article-title><source>Neurology</source><year>2001</year><volume>56</volume><fpage>537</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">11222803</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname><given-names>GM</given-names></name><name><surname>Godersky</surname><given-names>JC</given-names></name><name><surname>Biller</surname><given-names>J</given-names></name><name><surname>Hart</surname><given-names>MN</given-names></name><name><surname>Adams</surname><given-names>HP</given-names><suffix>Jr</suffix></name></person-group><article-title>Surgical experience with cerebral amyloid angiopathy</article-title><source>Stroke</source><year>1990</year><volume>21</volume><fpage>1545</fpage><lpage>1549</lpage><pub-id pub-id-type="pmid">2237947</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>SM</given-names></name><name><surname>Rebeck</surname><given-names>GW</given-names></name><name><surname>Vonsattel</surname><given-names>JP</given-names></name><name><surname>Gomez-Isla</surname><given-names>T</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><article-title>Apolipoprotein E &#x003b5;4 and cerebral hemorrhage associated with amyloid angiopathy</article-title><source>Ann Neurol</source><year>1995</year><volume>38</volume><fpage>254</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">7654074</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Premkumar</surname><given-names>DR</given-names></name><name><surname>Cohen</surname><given-names>DL</given-names></name><name><surname>Hedera</surname><given-names>P</given-names></name><name><surname>Friedland</surname><given-names>RP</given-names></name><name><surname>Kalaria</surname><given-names>RN</given-names></name></person-group><article-title>Apolipoprotein E-&#x003b5;4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer&#x02019;s disease</article-title><source>Am J Pathol</source><year>1996</year><volume>148</volume><fpage>2083</fpage><lpage>2095</lpage><pub-id pub-id-type="pmid">8669492</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicoll</surname><given-names>JA</given-names></name><name><surname>Burnett</surname><given-names>C</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Graham</surname><given-names>DI</given-names></name><name><surname>Dewar</surname><given-names>D</given-names></name><name><surname>Ironside</surname><given-names>JW</given-names></name><etal/></person-group><article-title>High frequency of apolipoprotein E &#x003b5;2 allele in hemorrhage due to cerebral amyloid angiopathy</article-title><source>Ann Neurol</source><year>1997</year><volume>41</volume><fpage>716</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">9189032</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brouwers</surname><given-names>HB</given-names></name><name><surname>Biffi</surname><given-names>A</given-names></name><name><surname>McNamara</surname><given-names>KA</given-names></name><name><surname>Ayres</surname><given-names>AM</given-names></name><name><surname>Valant</surname><given-names>V</given-names></name><name><surname>Schwab</surname><given-names>K</given-names></name><etal/></person-group><article-title>Apolipoprotein E genotype is associated with CT angiography spot sign in lobar intracerebral hemorrhage</article-title><source>Stroke</source><year>2012</year><volume>43</volume><fpage>2120</fpage><lpage>2125</lpage><pub-id pub-id-type="pmid">22621984</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>HC</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Knudsen</surname><given-names>KA</given-names></name><name><surname>Furie</surname><given-names>KL</given-names></name><name><surname>Segal</surname><given-names>AZ</given-names></name><name><surname>Chiu</surname><given-names>RI</given-names></name><etal/></person-group><article-title>Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><fpage>240</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">10648765</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maxwell</surname><given-names>SS</given-names></name><name><surname>Jackson</surname><given-names>CA</given-names></name><name><surname>Paternoster</surname><given-names>L</given-names></name><name><surname>Cordonnier</surname><given-names>C</given-names></name><name><surname>Thijs</surname><given-names>V</given-names></name><name><surname>Al-Shahi Salman</surname><given-names>R</given-names></name><etal/></person-group><article-title>Genetic associations with brain microbleeds: systematic review and meta-analyses</article-title><source>Neurology</source><year>2011</year><volume>77</volume><fpage>158</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">21715706</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leclercq</surname><given-names>PD</given-names></name><name><surname>Murray</surname><given-names>LS</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Graham</surname><given-names>DI</given-names></name><name><surname>Nicoll</surname><given-names>JA</given-names></name><name><surname>Gentleman</surname><given-names>SM</given-names></name></person-group><article-title>Cerebral amyloid angiopathy in traumatic brain injury: association with apolipoprotein E genotype</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2005</year><volume>76</volume><fpage>229</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">15654038</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamaguchi</surname><given-names>T</given-names></name><name><surname>Okino</surname><given-names>S</given-names></name><name><surname>Sodeyama</surname><given-names>N</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Otomo</surname><given-names>E</given-names></name><etal/></person-group><article-title>Association of a polymorphism of the transforming growth factor-&#x003b2;1 gene with cerebral amyloid angiopathy</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2005</year><volume>76</volume><fpage>696</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">15834029</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peila</surname><given-names>R</given-names></name><name><surname>Yucesoy</surname><given-names>B</given-names></name><name><surname>White</surname><given-names>LR</given-names></name><name><surname>Johnson</surname><given-names>V</given-names></name><name><surname>Kashon</surname><given-names>ML</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><etal/></person-group><article-title>A TGF-&#x003b2;1 polymorphism association with dementia and neuropathologies: the HAAS</article-title><source>Neurobiol Aging</source><year>2007</year><volume>28</volume><fpage>1367</fpage><lpage>1373</lpage><pub-id pub-id-type="pmid">16904244</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M</given-names></name></person-group><article-title>Cerebral amyloid angiopathy and gene polymorphisms</article-title><source>J Neurol Sci</source><year>2004</year><volume>226</volume><fpage>41</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">15537517</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Sodeyama</surname><given-names>N</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Suematsu</surname><given-names>N</given-names></name><name><surname>Otomo</surname><given-names>E</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of presenilin-1 polymorphism with cerebral amyloid angiopathy in the elderly</article-title><source>Stroke</source><year>1997</year><volume>28</volume><fpage>2219</fpage><lpage>2221</lpage><pub-id pub-id-type="pmid">9368568</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Sodeyama</surname><given-names>N</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Suematsu</surname><given-names>N</given-names></name><name><surname>Otomo</surname><given-names>E</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of &#x003b1;1-antichymotrypsin polymorphism with cerebral amyloid angiopathy</article-title><source>Ann Neurol</source><year>1998</year><volume>44</volume><fpage>129</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">9667601</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Sodeyama</surname><given-names>N</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Otomo</surname><given-names>E</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of neprilysin polymorphism with cerebral amyloid angiopathy</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2003</year><volume>74</volume><fpage>749</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">12754344</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christoforidis</surname><given-names>M</given-names></name><name><surname>Schober</surname><given-names>R</given-names></name><name><surname>Krohn</surname><given-names>K</given-names></name></person-group><article-title>Genetic-morphologic association study: association between the low density lipoprotein-receptor related protein (LRP) and cerebral amyloid angiopathy</article-title><source>Neuropathol Appl Neurobiol</source><year>2005</year><volume>31</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">15634227</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domingues-Montanari</surname><given-names>S</given-names></name><name><surname>Hernandez-Guillamon</surname><given-names>M</given-names></name><name><surname>Fernandez-Cadenas</surname><given-names>I</given-names></name><name><surname>Mendioroz</surname><given-names>M</given-names></name><name><surname>Boada</surname><given-names>M</given-names></name><name><surname>Munuera</surname><given-names>J</given-names></name><etal/></person-group><article-title>ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy</article-title><source>Neurobiol Aging</source><year>2011</year><volume>32</volume><fpage>551</fpage><pub-id pub-id-type="pmid">20381197</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Papassotiropoulos</surname><given-names>A</given-names></name><name><surname>Saido</surname><given-names>TC</given-names></name><name><surname>Griffin</surname><given-names>WS</given-names></name><name><surname>Mrak</surname><given-names>RE</given-names></name><name><surname>Kolsch</surname><given-names>H</given-names></name><etal/></person-group><article-title>Capillary cerebral amyloid angiopathy identifies a distinct APOE &#x003b5;4-associated subtype of sporadic Alzheimer's disease</article-title><source>Acta Neuropathol</source><year>2010</year><volume>120</volume><fpage>169</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">20535486</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biffi</surname><given-names>A</given-names></name><name><surname>Shulman</surname><given-names>JM</given-names></name><name><surname>Jagiella</surname><given-names>JM</given-names></name><name><surname>Cortellini</surname><given-names>L</given-names></name><name><surname>Ayres</surname><given-names>AM</given-names></name><name><surname>Schwab</surname><given-names>K</given-names></name><etal/></person-group><article-title>Genetic variation at CR1 increases risk of cerebral amyloid angiopathy</article-title><source>Neurology</source><year>2012</year><volume>78</volume><fpage>334</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">22262751</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arima</surname><given-names>H</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>C</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><name><surname>Bousser</surname><given-names>MG</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial</article-title><source>Stroke</source><year>2010</year><volume>41</volume><fpage>394</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">20044530</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Hylek</surname><given-names>EM</given-names></name><name><surname>O'Donnell</surname><given-names>HC</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name></person-group><article-title>Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study</article-title><source>Neurology</source><year>2000</year><volume>55</volume><fpage>947</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">11061249</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarron</surname><given-names>MO</given-names></name><name><surname>Nicoll</surname><given-names>JA</given-names></name></person-group><article-title>Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage</article-title><source>Lancet Neurol</source><year>2004</year><volume>3</volume><fpage>484</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">15261609</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charidimou</surname><given-names>A</given-names></name><name><surname>Kakar</surname><given-names>P</given-names></name><name><surname>Fox</surname><given-names>Z</given-names></name><name><surname>Werring</surname><given-names>DJ</given-names></name></person-group><article-title>Cerebral microbleeds and the risk of intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: systematic review and meta-analysis</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2013</year><volume>84</volume><fpage>277</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">23024352</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charidimou</surname><given-names>A</given-names></name><name><surname>Shakeshaft</surname><given-names>C</given-names></name><name><surname>Werring</surname><given-names>DJ</given-names></name></person-group><article-title>Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk</article-title><source>Front Neurol</source><year>2012</year><volume>3</volume><fpage>133</fpage><pub-id pub-id-type="pmid">23015806</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falcone</surname><given-names>GJ</given-names></name><name><surname>Radmanesh</surname><given-names>F</given-names></name><name><surname>Brouwers</surname><given-names>HB</given-names></name><name><surname>Battey</surname><given-names>TW</given-names></name><name><surname>Devan</surname><given-names>WJ</given-names></name><name><surname>Valant</surname><given-names>V</given-names></name><etal/></person-group><article-title>APOE &#x003b5; variants increase risk of warfarin-related intracerebral hemorrhage</article-title><source>Neurology</source><year>2014</year><volume>83</volume><fpage>1139</fpage><lpage>1146</lpage><pub-id pub-id-type="pmid">25150286</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vernooij</surname><given-names>MW</given-names></name><name><surname>Haag</surname><given-names>MD</given-names></name><name><surname>van der Lugt</surname><given-names>A</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Krestin</surname><given-names>GP</given-names></name><name><surname>Stricker</surname><given-names>BH</given-names></name><etal/></person-group><article-title>Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study</article-title><source>Arch Neurol</source><year>2009</year><volume>66</volume><fpage>714</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">19364926</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoonsen</surname><given-names>H</given-names></name><name><surname>Richard</surname><given-names>E</given-names></name><name><surname>Bentham</surname><given-names>P</given-names></name><name><surname>Gray</surname><given-names>R</given-names></name><name><surname>van Geloven</surname><given-names>N</given-names></name><name><surname>De Haan</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern?</article-title><source>Stroke</source><year>2010</year><volume>41</volume><fpage>2690</fpage><lpage>2692</lpage><pub-id pub-id-type="pmid">20930165</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boche</surname><given-names>D</given-names></name><name><surname>Zotova</surname><given-names>E</given-names></name><name><surname>Weller</surname><given-names>RO</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Neal</surname><given-names>JW</given-names></name><name><surname>Pickering</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Consequence of A&#x003b2; immunization on the vasculature of human Alzheimer's disease brain</article-title><source>Brain</source><year>2008</year><volume>131</volume><fpage>3299</fpage><lpage>3299</lpage><pub-id pub-id-type="pmid">18953056</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orgogozo</surname><given-names>JM</given-names></name><name><surname>Gilman</surname><given-names>S</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Laurent</surname><given-names>B</given-names></name><name><surname>Puel</surname><given-names>M</given-names></name><name><surname>Kirby</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Subacute meningoencephalitis in a subset of patients with AD after A&#x003b2;42 immunization</article-title><source>Neurology</source><year>2003</year><volume>61</volume><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">12847155</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicoll</surname><given-names>JA</given-names></name><name><surname>Wilkinson</surname><given-names>D</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Steart</surname><given-names>P</given-names></name><name><surname>Markham</surname><given-names>H</given-names></name><name><surname>Weller</surname><given-names>RO</given-names></name></person-group><article-title>Neuropathology of human Alzheimer disease after immunization with amyloid-&#x003b2; peptide: a case report</article-title><source>Nat Med</source><year>2003</year><volume>9</volume><fpage>448</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">12640446</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sperling</surname><given-names>R</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Tampieri</surname><given-names>D</given-names></name><name><surname>Barakos</surname><given-names>J</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><etal/></person-group><article-title>Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis</article-title><source>Lancet Neurol</source><year>2012</year><volume>11</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">22305802</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>C</given-names></name><name><surname>Estergard</surname><given-names>W</given-names></name><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Suhy</surname><given-names>J</given-names></name><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Siemers</surname><given-names>E</given-names></name><etal/></person-group><article-title>Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">21784350</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Porte</surname><given-names>SL</given-names></name><name><surname>Bollini</surname><given-names>SS</given-names></name><name><surname>Lanz</surname><given-names>TA</given-names></name><name><surname>Abdiche</surname><given-names>YN</given-names></name><name><surname>Rusnak</surname><given-names>AS</given-names></name><name><surname>Ho</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Structural basis of C-terminal &#x003b2;-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease</article-title><source>J Mol Biol</source><year>2012</year><volume>421</volume><fpage>525</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">22197375</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyoshi</surname><given-names>I</given-names></name><name><surname>Fujimoto</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Cronenberger</surname><given-names>C</given-names></name><etal/></person-group><article-title>Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer&#x02019;s disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study</article-title><source>Int J Clin Pharmacol Ther</source><year>2013</year><volume>51</volume><fpage>911</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">24131736</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>AH</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Ross</surname><given-names>J</given-names></name><name><surname>Styren</surname><given-names>S</given-names></name><name><surname>Landen</surname><given-names>JW</given-names></name><name><surname>Ma</surname><given-names>WW</given-names></name><etal/></person-group><article-title>Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease</article-title><source>Clin Neuropharmacol</source><year>2013</year><volume>36</volume><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">23334069</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landen</surname><given-names>JW</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Borrie</surname><given-names>M</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><name><surname>Billing</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study</article-title><source>Clin Neuropharmacol</source><year>2013</year><volume>36</volume><fpage>14</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">23334070</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="webpage"><collab>ClinicalTrials.gov</collab><year>2014</year><date-in-citation content-type="access-date">Accessed on November 7</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link></comment></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Revesz</surname><given-names>T</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Plant</surname><given-names>G</given-names></name><name><surname>Frangione</surname><given-names>B</given-names></name><name><surname>Rostagno</surname><given-names>A</given-names></name><etal/></person-group><article-title>Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies</article-title><source>Acta Neuropathol</source><year>2009</year><volume>118</volume><fpage>115</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">19225789</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Guillamon</surname><given-names>M</given-names></name><name><surname>Martinez-Saez</surname><given-names>E</given-names></name><name><surname>Delgado</surname><given-names>P</given-names></name><name><surname>Domingues-Montanari</surname><given-names>S</given-names></name><name><surname>Boada</surname><given-names>C</given-names></name><name><surname>Penalba</surname><given-names>A</given-names></name><etal/></person-group><article-title>MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke</article-title><source>Brain Pathol</source><year>2012</year><volume>22</volume><fpage>133</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">21707819</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Yin</surname><given-names>K</given-names></name><name><surname>Hsin</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Fryer</surname><given-names>JD</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage</article-title><source>J Neurol Sci</source><year>2005</year><volume>229-230</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">15760647</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarron</surname><given-names>MO</given-names></name><name><surname>Nicoll</surname><given-names>JA</given-names></name><name><surname>Stewart</surname><given-names>J</given-names></name><name><surname>Ironside</surname><given-names>JW</given-names></name><name><surname>Mann</surname><given-names>DM</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><etal/></person-group><article-title>The apolipoprotein E &#x003b5;2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage</article-title><source>J Neuropathol Exp Neurol</source><year>1999</year><volume>58</volume><fpage>711</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">10411341</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biffi</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>CD</given-names></name><name><surname>Jagiella</surname><given-names>JM</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Kissela</surname><given-names>B</given-names></name><name><surname>Hansen</surname><given-names>BM</given-names></name><etal/></person-group><article-title>APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study</article-title><source>Lancet Neurol</source><year>2011</year><volume>10</volume><fpage>702</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">21741316</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>CAA and CAA-associated vasculopathies. Massive amyloid deposition of amyloid fibrils with degeneration of smooth muscle cells in the media (A). Microaneurysmal dilatation (arrow) with fibrinoid necrosis (<sup>*</sup>) (B). Thickening of the intima (arrow) and double barreling of vascular walls (arrowheads) (C). (A, electron micrograph, bar=1 &#x000b5;m; B, Congo red, original magnification 110&#x000d7;; C, Congo red, original magnification 170&#x000d7;).</p></caption><graphic xlink:href="jos-17-17-g001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Immunohistochemistry of adjacent brain sections with antibodies to A&#x003b2;40 (A) and A&#x003b2;42 (B). Positive immunoreactivity to A&#x003b2;40 is mainly observed in vessel walls (CAA) (A), whereas A&#x003b2;42 immunoreactivity is mainly observed in the brain parenchyma (senile plaques) (B).</p></caption><graphic xlink:href="jos-17-17-g002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Pathophysiology of cerebral amyloid angiopathy (CAA)-related disorders. A&#x003b2; shows parenchymal (senile plaques) or vascular deposition (CAA) depending on dominance of A&#x003b2;42 or A&#x003b2;40, respectively. CAA is related to stroke and dementia. Hx, hemorrhagic events; Ix, ischemic events; IR, immune reaction against A&#x003b2;.</p></caption><graphic xlink:href="jos-17-17-g003"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Imaging findings of CAA-related hemorrhages and white matter lesions. Fresh (arrow) and old (arrowhead) lobar macrohemorrhages in the frontal lobes on CT (A). Cortical microhemorrhages with lobar distribution (B) and focal subarachnoid hemorrhages (superficial siderosis) (C) on gradient echo T2<sup>*</sup>-weighted MRI. Posterior distribution of white matter hyperintensities (arrows on T2-weighted MRI) (D).</p></caption><graphic xlink:href="jos-17-17-g004"/></fig><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Amyloid positron emission tomography (PET) using 11C-Pittsburgh Compound B (PiB) (A) with gradient echo T2<sup>*</sup>-weighted MRI (B) in a non-demented patient with multiple CAA-related intracerebral hemorrhages and disseminated cortical superficial siderosis. The left parietal region with an old intracerebral hemorrhage shows a relative scarcity of PiB uptake.</p></caption><graphic xlink:href="jos-17-17-g005"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Classification of cerebral amyloid angiopathy (CAA)</p></caption><graphic xlink:href="jos-17-17-i001"/></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Classic<xref rid="B83" ref-type="bibr">83</xref><sup>*</sup> and modified Boston criteria<xref rid="B32" ref-type="bibr">32</xref><sup>&#x02020;</sup> for diagnosis of CAA-related hemorrhage</p></caption><graphic xlink:href="jos-17-17-i002"/><table-wrap-foot><fn><p><sup>*</sup>Criteria established by the Boston Cerebral Amyloid Angiopathy Group: Steven M. Greenberg, MD, PhD, Daniel S. Kanter, MD, Carlos S. Kase, MD, and Michael S. Pessin, MD.</p><p><sup>&#x02020;</sup>The modified criteria are indicated in [ ].</p><p><sup>&#x02021;</sup>As defined in: Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. <italic>Ann Neurol</italic> 1991;30:637-649.</p><p><sup>&#x000a7;</sup>Siderosis restricted to 3 or fewer sulci.</p><p><sup>&#x02225;</sup>Siderosis affecting at least 4 sulci.</p><p><sup>&#x000b6;</sup>Other causes of intracerebral hemorrhage: excessive warfarin (international normalization ratio, INR&#x0003e;3.0); antecedent head trauma or ischemic stroke; central nervous system tumor, vascular malformation, or vasculitis; and blood dyscrasia or coagulopathy. INR&#x0003e;3.0 or other nonspecific laboratory abnormalities permitted for diagnosis of possible CAA.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Biomarkers and risk factors for cerebral amyloid angiopathy (CAA) and CAA-related disorders</p></caption><graphic xlink:href="jos-17-17-i003"/><table-wrap-foot><fn><p><sup>*</sup>Gradient echo T2<sup>*</sup> or susceptibility-weighted images are recommended to detect microhemorrhages or focal superficial siderosis.</p><p><sup>&#x02020;</sup>Future development of MRI scanners with a higher spatial resolution is necessary to detect cortical microinfarcts.</p><p><sup>&#x02021;</sup>Some mutations in the amyloid &#x003b2;-protein precursor (A&#x003b2;PP) and presenilin genes are associated with severe CAA [see review<xref rid="B5" ref-type="bibr">5</xref>].</p></fn></table-wrap-foot></table-wrap></floats-group></article>